NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression ...Middle East

FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine has become widely used for treating depression and suicidality but has never been presented to FDA for approval Potential to file New Drug Application for Ketamine in...

Hence then, the article about nrx pharmaceuticals announces signing of a development agreement for the manufacture of ketamine to treat suicidality and depression was published today ( Tuesday 31/10/2023 - 01:56 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression )

Also on site :

• Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
• Reported tornado rips roofs off multiple homes in central Illinois
• John Legend Celebrates 47th Birthday With Family Slime Outing in New York